Lead Time of the Methotrexate Establishment and Vaccinal Protection Against the Pneumococcal Agent in Patients Affected With Rheumatoid Polyarthritis

Trial Profile

Lead Time of the Methotrexate Establishment and Vaccinal Protection Against the Pneumococcal Agent in Patients Affected With Rheumatoid Polyarthritis

Recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Sep 2015

At a glance

  • Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary) ; Pneumococcal vaccine
  • Indications Pneumococcal infections
  • Focus Pharmacodynamics; Registrational
  • Acronyms VACIMRA
  • Most Recent Events

    • 31 Aug 2015 Planned End Date changed from 1 Sep 2016 to 1 Mar 2018 as per ClinicalTrials.gov record.
    • 31 Aug 2015 Planned primary completion date changed from 1 Sep 2015 to 1 Apr 2017 as per ClinicalTrials.gov record.
    • 08 Jan 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top